GSTM1 and cancer: We planned to compare a model‐based strategy to the NICE f‐HB cut off of 10 μg/g and a risk of referral threshold of 3% (f‐Hb ≥ 40 μg/g and others including a 1% and 2% risk) akin to the NICE early cancer diagnosis recommendations and assess diagnostic utility using a net benefit approach [6].